MedPath

JY-231

Generic Name
JY-231

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Jun 3, 2025

Vilanterol: A Comprehensive Pharmacological and Clinical Review

1. Introduction to Vilanterol

1.1. Background and Development

Vilanterol is a selective long-acting β2​-adrenergic agonist (LABA) distinguished by its inherent 24-hour activity, permitting once-daily administration for the management of Chronic Obstructive Pulmonary Disease (COPD) and asthma.[1] The impetus for its development stemmed from a clinical need to enhance patient compliance, which is often suboptimal with regimens requiring more frequent dosing or complex administration techniques.[1] This focus on simplifying treatment regimens addresses a significant barrier in chronic respiratory disease management, potentially leading to improved disease control and patient outcomes. This approach is further supported by pharmacoeconomic analyses suggesting adherence benefits for once-daily therapies.[2]

The molecular design of Vilanterol is rooted in the salmeterol scaffold. It was specifically engineered as an antedrug analog of salmeterol, involving modifications to produce homochiral compounds with the (R)-configuration at the chiral benzylic alcohol carbon.[1] This targeted chemical modification aimed to optimize the pharmacological profile, particularly to achieve a duration of action suitable for once-daily dosing, a characteristic that differentiates it from some earlier LABAs like salmeterol, which typically requires twice-daily administration.[1] The development of Vilanterol, particularly the active substance, involved a collaboration between Innoviva (formerly Theravance) and GlaxoSmithKline (GSK). GSK is the primary manufacturer of Vilanterol-containing products, and Innoviva receives royalties from their sales.[3]

1.2. Drug Class and Therapeutic Significance

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/07/15
Not Applicable
Recruiting
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
2025/04/23
Not Applicable
Recruiting
Affiliated Hospital of Guangdong Medical University
2025/03/30
Not Applicable
Not yet recruiting
He Huang
2025/03/21
Not Applicable
Recruiting
Shenzhen Genocury Biotech Co., Ltd.
2025/03/21
Not Applicable
Not yet recruiting
He Huang
2025/03/17
Not Applicable
Not yet recruiting
He Huang
2025/01/28
Not Applicable
Recruiting
2024/11/15
Not Applicable
Recruiting
2024/11/07
Not Applicable
Recruiting
Shenzhen Genocury Biotech Co., Ltd.
2024/11/05
Phase 1
Recruiting
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.